May 23, 2012
Dr. Glen Goss, University of Ottawa and NCI-Canada Lung Cancer Committee chair, discusses the potential and limitations of integrating molecular marker studies in advanced non-small cell lung cancer patients across a health care...
May 23, 2012
Dr. Glen Goss, University of Ottawa and NCI-Canada Lung Cancer Committee chair, discusses the potential and limitations of integrating molecular marker studies in advanced non-small cell lung cancer patients across a health care system.
May 10, 2012
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the benefits and challenges of conducting trials that include patient subgroups based on molecular markers.
May 10, 2012
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the benefits and challenges of conducting trials that include patient subgroups based on molecular markers.